公开(公告)号：US20170020887A1

公开(公告)日：2017-01-26

申请号：US15079934

申请日：2016-03-24

Applicant: Megumi Honjo ,  KOWA COMPANY, LTD.

Inventor： Megumi Honjo ,  Eiji Wato ,  Masayuki Ohta

IPC: A61K31/551 ,  A61K9/08 ,  A61K9/00

CPC classification number: A61K31/551 ,  A61K9/0048 ,  A61K9/08

Abstract: The present invention provides a method for the prevention and treatment of complications after cataract surgery such as secondary cataract and anterior capsule contraction that occur after cataract operation.The present invention relates to a preventive/therapeutic method comprising administering to a subject a medicine containing 4-fluoro-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline (Ripasudil) or a salt thereof, or a solvate thereof as an active ingredient.

Abstract translation: 本发明涉及一种预防/治疗方法，其包括向受试者施用含有4-氟-5 - {[（2S）-2-甲基-1,4-二氮杂环庚烷-1-基]磺酰基}异喹啉（Ripasudil） 或其盐或其溶剂合物作为活性成分。

公开(公告)号：US20200297723A1

公开(公告)日：2020-09-24

申请号：US16898920

申请日：2020-06-11

Applicant: KOWA COMPANY, LTD.

Inventor： Yoshio KANEKO ,  Masayuki Ohta

IPC: A61K31/498 ,  A61K45/00 ,  A61K47/22 ,  A61K31/551 ,  A61P27/06

Abstract: A pharmacotherapy is provided for preventing glaucoma or preventing or treating ocular hypertension, the pharmacotherapy providing potent intraocular pressure-lowering action with fast-acting properties and prolonged duration. A combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or the salt thereof and an α2 agonist for preventing or treating glaucoma.

公开(公告)号：US09844556B2

公开(公告)日：2017-12-19

申请号：US15079934

申请日：2016-03-24

Applicant: Megumi Honjo ,  KOWA COMPANY, LTD.

Inventor： Megumi Honjo ,  Eiji Wato ,  Masayuki Ohta

IPC: A61K31/551 ,  A61K9/00 ,  A61K9/08

CPC classification number: A61K31/551 ,  A61K9/0048 ,  A61K9/08

Abstract: The present invention provides a method for the prevention and treatment of complications after cataract surgery such as secondary cataract and anterior capsule contraction that occur after cataract operation.The present invention relates to a preventive/therapeutic method comprising administering to a subject a medicine containing 4-fluoro-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline (Ripasudil) or a salt thereof, or a solvate thereof as an active ingredient.